Phase II data from the NeoPalAna trial conclude that the combination of neoadjuvant palbociclib and anastrozole induces a higher rate of complete cell-cycle arrest (defined as Ki67 ≤ 2.7%) than anastrozole alone in patients with clinical stage II/III HR + breast cancer [16]. This evidence concerns the gene MKI67 and breast carcinoma.